Skip to content
OpenCapital
Get started
Income StatementBalance SheetCash FlowSegments
Becton, Dickinson and Company logo

Becton, Dickinson and Company Business Segments

Business, geographic, and product segment breakdowns

Becton, Dickinson and Company generates $21.4B in annual revenue across 4 key segments: BioPharma Systems ($590.0M), Connected Care ($1.1B), Interventional ($5.4B), and Medical Essentials ($1.6B). The company-wide operating margin is 10.41%. Based on the Q1 2026 filing.

BioPharma Systems$590.0MConnected Care$1.1BInterventional (TTM)$5.4BMedical Essentials$1.6B
Latest FilingQ1 2026
Report Date2026-05-07
Market Cap$40.6B
P/E Ratio35.68
ROE4.61%

Products & Services

Revenue, remaining performance obligation, amount

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Products and/or Services$2.3B$2.4B$2.5B$2.8B$2.5B$2.3B
Consumables$2B$2.2B$2.3B$2.3B$2.4B$2B

Loss contingency accrual, product liability, net

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Pyxis$50M$124M$114M$98M$83M$68M

Selling and administrative expense

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shipping and Handling$184M$184M$184M$184M——

Geographic

Long-Lived Assets

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
EMEA———$6.8B——
Greater Asia———$1.6B——
Other———$2.4B——
United States———$34.8B——

Revenue

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
UNITED STATES$3.1B$2.8B$3.2B$3.4B$3.2B$2.9B
International$2.1B$1.7B$2.3B$2.5B$2.1B$1.8B
EMEA$1.2B$1.2B$1.2B$1.2B——
Greater Asia$773.3M$773.3M$773.3M$773.3M——
Other$306.8M$306.8M$306.8M$306.8M——

Pension settlement expense

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
United States$9.5M$9.5M$9.5M$9.5M——

Business Segments

Cost of products sold

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Medical Essentials$770M$743M——$800M$835M
Connected Care$483M$478M——$501M$490M
Interventional$404M$401M——$445M$429M
BioPharma Systems$232M$306M——$243M$316M
Medical$1.4B$1.4B$1.4B$1.4B——

D&A

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Connected Care$194M$199M——$194M$194M
Interventional$200M$198M——$197M$192M
Medical Essentials$135M$136M——$141M$147M
BioPharma Systems$31M$32M——$34M$27M
Medical$348.3M$348.3M$348.3M$348.3M——

Goodwill

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Interventional$12.7B$12.7B$12.8B$12.8B$12.8B$12.8B
Medical Essentials———$7B$7B$7B
Connected Care———$6.1B$6.1B$6.1B
BioPharma Systems———$96M$96M$96M

Goodwill, Foreign Currency Translation, Gain (Loss)

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Interventional$66M-$24M-$69M-$8M-$3M$13M
Medical Essentials————-$4M$6M
Connected Care————-$1M-$1M
BioPharma Systems————$0$0

Operating Income (Loss)

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Interventional$561M$565M——$561M$579M
Medical Essentials$607M$617M——$569M$574M
Connected Care$336M$353M——$352M$347M
BioPharma Systems$141M$224M——$140M$225M

Other Operating Income

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Connected Care-$6M-$2M——-$3M-$3M
BioPharma Systems$0$0——$0$0
Interventional$0$0——$0$0
Medical Essentials$0$0——$0$0
Medical$4.3M$4.3M$4.3M$4.3M——

Research and development expense

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Connected Care$80M$74M——$85M$90M
Interventional$56M$63M——$63M$72M
Medical Essentials$44M$48M——$47M$53M
BioPharma Systems$17M$18M——$18M$17M
Medical$130.8M$130.8M$130.8M$130.8M——

Revenue

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Medical Essentials$1.6B$1.6B——$1.6B$1.6B
Interventional$1.3B$1.3B$1.3B$1.4B$1.3B$1.4B
Connected Care$1.1B$1.1B——$1.1B$1.1B
BioPharma Systems$418M$575M——$429M$590M

Segment Cost of Products and Services Sold as a Percent of Revenues

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
BioPharma Systems55.4%53.2%——56.6%53.6%
Medical Essentials48.5%47.0%——50.1%50.7%
Connected Care45.0%44.8%——44.3%43.7%
Interventional32.1%31.7%——33.5%31.6%

Segment Operating Income (Loss) as a Percent of Revenues

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Interventional44.6%44.7%——42.1%42.7%
BioPharma Systems33.7%38.9%——32.6%38.1%
Medical Essentials38.3%39.3%——35.6%34.8%
Connected Care31.3%33.0%——31.1%31.0%

Segment Other Operating Expense (Income), net as a Percent of Revenues

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Connected Care0.6%0.2%——0.3%0.3%
BioPharma Systems0.0%0.0%——0.0%0.0%
Interventional0.0%0.0%——0.0%0.0%
Medical Essentials0.0%0.0%——0.0%0.0%
Medical0.1%0.1%0.1%0.1%——

Segment Research and Development as a Percent of Revenues

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Connected Care7.4%6.9%——7.5%8.1%
Interventional4.4%5.0%——4.7%5.3%
Medical Essentials2.8%3.1%——2.9%3.2%
BioPharma Systems4.1%3.1%——4.1%2.8%
Medical1.1%1.1%1.1%1.1%——

Segment Selling and Administrative as a Percent of Revenues

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Interventional18.9%18.6%——19.7%20.4%
Connected Care15.7%15.1%——16.9%17.0%
Medical Essentials10.4%10.4%——11.3%11.2%
BioPharma Systems6.8%4.8%——6.6%5.4%
Medical2.9%2.9%2.9%2.9%——

Selling and administrative expense

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Interventional$237M$236M——$262M$277M
Connected Care$168M$161M——$191M$190M
Medical Essentials$165M$164M——$180M$185M
BioPharma Systems$29M$28M——$29M$32M
Medical$328M$328M$328M$328M——

Cost of Products Sold as a Percent of Revenues

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Medical11.9%11.9%11.9%11.9%——

Reconciliation of Operating Profit (Loss) from Segments to Consolidated

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Medical$1B$1B$1B$1B——

Segment, Expenditure, Addition to Long-Lived Assets

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Medical$117.3M$117.3M$117.3M$117.3M——

Segment Operating Income as a Percent of Revenues

SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Medical9.0%9.0%9.0%9.0%——